Kaynes Q4FY26 Miss: JPMorgan Downgrade Hits 2026

What triggered the sell-off on May 14

Kaynes Technology India Ltd shares fell sharply on May 14, 2026 after brokerages flagged a miss versus the company’s own guidance and Street expectations in the March quarter (Q4FY26). The fall followed a downgrade from JPMorgan, which cut its rating to ‘Neutral’ from ‘Overweight’ and reduced its target price. In early trade, the stock dropped as much as 19.4% to ₹3,366 from a previous close of ₹4,177.85. At 10:01 am, it was still down about 17% at ₹3,454.2.

The decline comes at a time when investors have been closely watching execution and balance sheet trends for electronics manufacturing services (EMS) companies. Kaynes is also coming off a steep correction, with the stock down more than 56% from its 52-week high of ₹7,705 hit in October 2025.

Q4FY26 profit fell 22% year-on-year

Kaynes reported consolidated net profit of ₹91 crore in Q4FY26, compared with ₹116 crore in the same quarter last year, a decline of about 22%. Another report pegged Q4FY26 net profit at ₹91.2 crore versus ₹116.2 crore, a 21.5% decline year-on-year. Broker notes cited weaker-than-expected performance across key operating metrics.

The profit pressure was also linked to cost line items highlighted in coverage. One report said finance costs doubled to ₹41 crore for the reported period, while depreciation rose 178%. These were cited as additional headwinds alongside working capital stress.

Revenue missed guidance and estimates

CLSA said Q4 revenue grew 26% year-on-year to ₹1,240 crore, but this was below its estimate of ₹1,570 crore and the company’s guidance of ₹1,700 crore. JPMorgan also flagged the scale of the miss, stating that Kaynes missed its own 4QFY27 revenue guidance by 27% and missed lowered Street and JPMorgan expectations by 18% and 13% respectively.

CLSA also said operating margin fell 150 basis points year-on-year to 15.6% versus its estimate of 16.5%. The mix of lower-than-guided revenue and softer profitability contributed to the market’s negative read-through.

Working capital remains the key pressure point

JPMorgan said net working capital (NWC) days stayed elevated at 125 days, versus guidance of 85 days. Nuvama Institutional Equities also pointed to a rise in working capital days from 87 to 125, alongside weaker-than-expected operating cash flow.

Nuvama said operating cash flow was negative ₹600 crore versus guidance of marginally negative to positive. CLSA similarly emphasised that the balance sheet “deteriorated further” heading into the results, keeping investor focus on cash conversion and receivables.

JPMorgan downgrade: what changed

JPMorgan cut Kaynes’ earnings estimates by 12% to 17% over the next two years, led by reductions across core EMS, OSAT, and PCB businesses. It also said it cut its core EMS multiple to 33x from 45x, citing lower revenue growth assumptions over the next two years and over the medium to long term in its DCF, alongside higher NWC days in the medium-term model.

JPMorgan assigned a ‘Neutral’ rating and set a target price of ₹4,000. Another report said the target price was reduced to ₹4,000 from ₹6,000 earlier, implying a cut of more than 33%.

Other brokerage reactions: CLSA and Nuvama

CLSA said the company missed its own guidance and Street expectations on operational parameters, and highlighted the balance sheet trend as a central concern. It also reported net debt at ₹71 crore, compared with FY25 net debt of ₹190 crore, based on its note.

Nuvama said Kaynes posted a weaker-than-expected quarter with revenue and EBITDA growth of 26% and 15% year-on-year, while adjusted PAT declined 21% year-on-year. It cut FY27E and FY28E EPS by 22% and 20% respectively to reflect a weak Q4 and a challenging near term. Nuvama reduced its target price to ₹3,550 from ₹5,500 and downgraded the stock to ‘Hold’.

Key reported numbers at a glance

Market impact: what investors reacted to

The immediate market reaction reflected two issues highlighted repeatedly by brokerages: execution versus guidance and cash conversion. The Q4 revenue print of ₹1,240 crore was well below the company’s stated guidance of ₹1,700 crore, and below CLSA’s estimate. At the same time, working capital remained elevated at 125 days versus the 85-day guidance cited by JPMorgan.

For investors, the combination matters because it directly affects operating cash flow and funding needs. With Nuvama pointing to negative operating cash flow of ₹600 crore versus guidance of marginally negative to positive, the market focus shifted from just top-line growth to the sustainability of growth and the balance sheet path.

Why the miss matters for the EMS narrative

Kaynes is positioned across multiple manufacturing segments, and JPMorgan’s cuts referenced core EMS, OSAT and PCB. When revenue misses coincide with an increase in net working capital days, broker models typically reduce near-term earnings and apply lower valuation multiples, as seen in JPMorgan’s shift to 33x from 45x for core EMS.

The day’s price action also reflected the sensitivity of mid-cap manufacturing stocks to guidance credibility. A sharp gap between guidance and reported outcomes often forces analysts to revisit growth and cash assumptions, which can quickly translate into rating changes and lower target prices.

Conclusion

Kaynes Technology’s May 14 decline followed a Q4FY26 performance that brokerages described as below guidance and expectations, alongside elevated working capital. JPMorgan’s downgrade to ‘Neutral’ with a ₹4,000 target price, and Nuvama’s EPS cuts and lower target, kept the focus on execution and cash conversion metrics. The next set of updates investors will watch are any company steps to bring working capital days down from 125 and improve operating cash flow after the March quarter.